NMPA approves Lilly Elamine ® (Barretini tablets) 2mg tablets for the treatment of severe active rheumatoid arthritis in adults

rheumatoid arthritis is a chronic inflammatory autoimmune disease that seriously affects the daily work and life of patients, thus affecting their quality of lifeRecent epidemiological surveys show that the prevalence of rheumatoid arthritis in Chinese mainland is 0.28%, the total number of people with the disease is about 5 million, and the incidence rate of men and women is aboutrecently, Lilly China announced that the NationalDrug(http://Regulatory Authority (NMPA) approved the use of 2mg tablets of the Elamine ® (Barretini tablets) for the treatment of severe active rheumatoid arthritis in adultsEllamine ® (Barretinis tablets) is a tyrosine protein kinase (JAK) 1/2 inhibitor administered daily orallyElamine ® (Barretini tablets) is suitable for adult patients with moderate to severe active rheumatoid arthritis who have poor or intolerant efficacy in one or more anti-rheumatism drugs (DMARD) and may be used in combination with methotrexate or other abioticlyimproved anti-rheumatism drugs1The ® is developed by LillyPharmaceuticalhttp://and http://, the http://medicalSince its launch in 2017, the ® of Elmartin (Barretini tablets) has reached 50,000 patients in more than 60 countries worldwide, and looks forward to bringing treatment hope to more immunopathions in the future